Treatment with everolimus is associated with a procoagulant state

Thrombosis Research

Volumn 132, Issue 2, 2013, Pages 307-311

  Baas, Marije C ^a   Gerdes, Victor E A ^a,b   Ten Berge, Ineke J M ^a   Heutinck, K M ^a   Florquin, S ^a   Meijers, Joost C M ^a   Bemelman, Frederike J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Slotervaartziekenhuis ^*  (Netherlands)

Author keywords

coagulation; everolimus; fibrinolysis; mTOR inhibitor; renal transplantation; thrombosis

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISOLONE; PROCOAGULANT; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FIBRINOLYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACADEMIC MEDICAL CENTER; ACTIVATED PARTIAL THROMBOPLASTIN TIME; ACTIVATED PROTEIN C; AMC; APC; APC SENSITIVITY RATIO; APCSR; APTT; AREA UNDER THE CURVE; AUC; CALCINEURIN INHIBITOR; CHRONIC KIDNEY DISEASE; CKD; CNI; COAGULATION; CSA; CYCLOSPORINE A; EGFR; ELISA; ENDOGENOUS THROMBIN POTENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTIMATED GFR; ETP; EVEROLIMUS; EVL; F1+2; FIBRINOLYSIS; MAMMALIAN TARGET OF RAPAMYCIN; MPS; MTOR; MTOR INHIBITOR; MTORI; MYCOPHENOLATE SODIUM; NON SIGNIFICANT; NS; P; PAI-1; PAP; PHOSPHOINOSITIDE 3-KINASE; PI3K; PLASMIN-ALPHA2-ANTIPLASMIN COMPLEXES; PLASMINOGEN ACTIVATOR INHIBITOR-1; PREDNISOLONE; PROTHROMBIN FRAGMENT 1+2; PROTHROMBIN TIME; PT; RENAL TRANSPLANTATION; TAFI; TF; THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOSIS; TISSUE FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF; VENOUS THROMBOEMBOLISM; VON WILLEBRAND FACTOR; VTE; VWF;

ADULT; BLOOD COAGULATION; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; TOR SERINE-THREONINE KINASES; VENOUS THROMBOSIS;

EID: 84883818084     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.07.004     Document Type: Article

References (38)

1. T.J. Rabelink, J.J. Zwaginga, H.A. Koomans, and J.J. Sixma Thrombosis and hemostasis in renal disease Kidney Int 46 1994 287 296
2. K. Wattanakit, M. Cushman, C. Stehman-Breen, S.R. Heckbert, and A.R. Folsom Chronic kidney disease increases risk for venous thromboembolism J Am Soc Nephrol 19 2008 135 140
3. K. Wattanakit, and M. Cushman Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms Curr Opin Pulm Med 15 2009 408 412
4. A. Humar, E.M. Johnson, K.J. Gillingham, D.E. Sutherland, W.D. Payne, and D.L. Dunn Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis Transplantation 65 1998 229 234
5. D. Poli, M. Zanazzi, E. Antonucci, E. Bertoni, M. Salvadori, and R. Abbate Renal transplant recipients are at high risk for both symptomatic and asymptomatic deep vein thrombosis J Thromb Haemost 4 2006 988 992
6. A.T. Rowshani, E.M. Scholten, F. Bemelman, M. Eikmans, M. Idu, and M.C. Roos-van Groningen No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year J Am Soc Nephrol 17 2006 305 312
7. M. Levi, J. Wilmink, H.R. Buller, J. Surachno, and J.W. ten Cate Impaired fibrinolysis in cyclosporine-treated renal transplant patients. Analysis of the defect and beneficial effect of fish-oil Transplantation 54 1992 978 983
8. G.M. Patrassi, M.T. Sartori, P. Rigotti, L.D. Di, P. Theodoridis, and M. Fioretti Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment Transplantation 59 1995 1416 1420
9. B. Pratap, G. Abraham, C.N. Srinivas, and S. Bhaskar Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus Saudi J Kidney Dis Transpl 18 2007 609 612
10. J.C. Reynolds, L.Y. Agodoa, C.M. Yuan, and K.C. Abbott Thrombotic microangiopathy after renal transplantation in the United States Am J Kidney Dis 42 2003 1058 1068
11. J.A. Saikali, L.D. Truong, and W.N. Suki Sirolimus may promote thrombotic microangiopathy Am J Transplant 3 2003 229 230
12. H. Sartelet, O. Toupance, M. Lorenzato, F. Fadel, L.H. Noel, and E. Lagonotte Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys Am J Transplant 5 2005 2441 2447
13. J.A. Muldowney III, J.R. Stringham, S.E. Levy, L.A. Gleaves, M. Eren, and R.N. Piana Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents Arterioscler Thromb Vasc Biol 27 2007 400 406
14. G.G. Camici, J. Steffel, I. Amanovic, A. Breitenstein, J. Baldinger, and S. Keller Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents Eur Heart J 31 2010 236 242
15. F.J. Bemelman, E.F. de Maar, R.R. Press, H.J. van Kan, I. ten Berge, and J.J. Homan van der Heide Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis Transplantation 88 2009 421 428
16. H.C. Hemker, P. Giesen, R. Al Dieri, V. Regnault, E. de Smedt, and R. Wagenvoord Calibrated automated thrombin generation measurement in clotting plasma Pathophysiol Haemost Thromb 33 2003 4 15
17. A.S. Levey, J. Coresh, T. Greene, L.A. Stevens, Y.L. Zhang, and S. Hendriksen Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate Ann Intern Med 145 2006 247 254
18. V. Horcicka, J. Zadrazil, D. Karasek, J.S. Al, K. Krejci, and P. Strebl Significance of HLA nondependent risk factors of chronic transplant nephropathy for the development of endothelial dysfunction after kidney transplantation Transplant Proc 41 2009 1599 1603
19. B. Huser, B. Lammle, J. Landmann, T.H. Tran, M. Oberholzer, and G.A. Marbet von Willebrand factor and factor VIII in renal transplant recipients under immunosuppression with cyclosporine and steroids. Sequential measurements over 4 months in 17 patients Clin Nephrol 34 1990 214 222
20. J. Malyszko, J.S. Malyszko, K. Pawlak, and M. Mysliwiec Endothelial function and novel adhesion molecule CD44 in kidney allograft recipients Transplant Proc 40 2008 3470 3473
21. M. Guba, M. Yezhelyev, M.E. Eichhorn, G. Schmid, I. Ischenko, and A. Papyan Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF Blood 105 2005 4463 4469
22. X.M. Nie, Y.J. Zhou, Y.F. Li, Y. Xie, and L.X. Su Effects of sirolimus upon endothelial thrombotic function of human umbilical vein endothelial cells Zhonghua Yi Xue Za Zhi 91 2011 1281 1284
23. M.D. Saemann, M. Haidinger, M. Hecking, W.H. Horl, and T. Weichhart The multifunctional role of mTOR in innate immunity: implications for transplant immunity Am J Transplant 9 2009 2655 2661
24. T. Weichhart, and M.D. Saemann The multiple facets of mTOR in immunity Trends Immunol 30 2009 218 226
25. M. Delvaeye, and E.M. Conway Coagulation and innate immune responses: can we view them separately? Blood 114 2009 2367 2374
26. G. Al-Massarani, H. Vacher-Coponat, P. Paul, A. Widemann, L. Arnaud, and A. Loundou Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation Am J Transplant 8 2008 2360 2367
27. H. Oflaz, A. Turkmen, F. Turgut, B. Pamukcu, S. Umman, and A. Ucar Changes in endothelial function before and after renal transplantation Transpl Int 19 2006 333 337
28. M.T. Sartori, P. Rigotti, F. Marchini, L. Spiezia, N. Baldan, and L. Furian Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunosuppression therapy Transplantation 75 2003 994 998
29. V.N. Ahya, P.J. McShane, M.A. Baz, V.G. Valentine, S.M. Arcasoy, and R.B. Love Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation J Heart Lung Transplant 30 2011 175 181
30. M. Montalbano, G.W. Neff, N. Yamashiki, D. Meyer, M. Bettiol, and G. Slapak-Green A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications Transplantation 78 2004 264 268
31. O. Sezer, H.A. Welp, M. Ozgun, D. Maintz, H.H. Scheld, and A. Hoffmeier Huge right atrial thrombus 6 years after heart transplantation Ann Thorac Surg 85 2008 343
32. M. Vanderheyden, M. Goethals, and F. Wellens Right atrial thrombosis in a heart transplant recipient after initiation of sirolimus Acta Cardiol 60 2005 229 232
33. H. Ekberg, C. Bernasconi, J. Noldeke, A. Yussim, L. Mjornstedt, and U. Erken Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study Nephrol Dial Transplant 25 2010 2004 2010
34. S.H. Tedesco Jr., D. Cibrik, T. Johnston, E. Lackova, K. Mange, and C. Panis Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients Am J Transplant 10 2010 1401 1413
35. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, and S. Bracarda Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
36. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, and S. Bracarda Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
37. H.K. Chew, T. Wun, D. Harvey, H. Zhou, and R.H. White Incidence of venous thromboembolism and its effect on survival among patients with common cancers Arch Intern Med 166 2006 458 464
38. T. Wun, and R.H. White Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors Cancer Invest 27 Suppl. 1 2009 63 74